Correspondence 0001213900-24-038999 from Virpax Pharmaceuticals, Inc. (VRPX) (CIK 0001708331)
Virpax Pharmaceuticals, Inc. (VRPX) (CIK 0001708331)
Date: May 2, 2024 · CIK: 0001708331 · Accession: 0001213900-24-038999
AI Filing Summary & Sentiment
File numbers found in text: 333-278796
Letter
VIA EDGAR United States Securities Division of Corporation Finance Attention: Daniel Crawford Re: Virpax Pharmaceuticals, Inc. Registration Statement on Form S-3 Filed April 18, 2024 File No: 333-278796
Dear Mr. Crawford:
Virpax Pharmaceuticals, Inc. (the “Registrant”) hereby requests that the effective date of the above-referenced Registration Statement on Form S-1, as amended (File No. 333-278796), be accelerated by the U.S. Securities and Exchange Commission (the “Commission”) to become effective today, Thursday, May 2, 2024, at 5:00 p.m., Eastern Time, or as soon as reasonably practicable thereafter.
The Registrant understands that the Staff of the Commission will consider this request as confirmation by the Registrant that it is aware of its responsibilities under the federal securities laws as they relate to the issuance of the securities covered by the Registration Statement.
The Registrant hereby authorizes Leslie Marlow and/or Melissa Palat Murawsky of Blank Rome LLP to orally modify or withdraw this request for acceleration. Please contact Ms. Marlow at (516) 457-4238, or Ms. Murawsky at (215) 569-5732 with any questions you may have concerning this request, and please notify either of them when this request for acceleration has been granted.
Very truly yours,
VIRPAX PHARMACEUITCALS, INC.
Show Raw Text
CORRESP
1
filename1.htm
May 2, 2024
VIA EDGAR
United States Securities
and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attention: Daniel Crawford
Re:
Virpax Pharmaceuticals, Inc.
Registration Statement on Form S-3
Filed April 18, 2024
File No: 333-278796
Dear Mr. Crawford:
Virpax Pharmaceuticals, Inc. (the
“Registrant”) hereby requests that the effective date of the above-referenced Registration Statement on Form S-1, as
amended (File No. 333-278796), be accelerated by the U.S. Securities and Exchange Commission (the “Commission”) to
become effective today, Thursday, May 2, 2024, at 5:00 p.m., Eastern Time, or as soon as reasonably practicable thereafter.
The Registrant understands
that the Staff of the Commission will consider this request as confirmation by the Registrant that it is aware of its responsibilities
under the federal securities laws as they relate to the issuance of the securities covered by the Registration Statement.
The Registrant hereby authorizes
Leslie Marlow and/or Melissa Palat Murawsky of Blank Rome LLP to orally modify or withdraw this request for acceleration. Please contact
Ms. Marlow at (516) 457-4238, or Ms. Murawsky at (215) 569-5732 with any questions you may have concerning this request, and please notify
either of them when this request for acceleration has been granted.
Very truly yours,
VIRPAX PHARMACEUITCALS, INC.
By:
/s/ Gerald Bruce
Name:
Gerald Bruce
Title:
Chief Executive Officer
cc: Leslie Marlow, Blank Rome LLP
Melissa Palat Murawsky, Blank Rome LLP